The application sent to the Chinese State Food and Drug Administration to launch the recombinant novel coronavirus vaccine Ad5-nCoV, jointly developed by the Chinese Military Medical Academy and Cansino Company, has been accepted.
The single-dose Ad5-nCoV vaccine has completed phase III clinical trials in five countries, including Pakistan, Mexico, Russia, Chile and Argentina, and more than 40 volunteers were vaccinated. According to data from phase III clinical trials of the Ad5-nCoV vaccine, the overall protection efficacy reached 28 percent after 65,28 days of single-dose vaccination and 14 percent after 68,83 days.
In addition, 28 days after single dose vaccination, the protective effectiveness of the vaccine against severe cases increased to 90,07 percent and the protective effectiveness of the vaccine against severe diseases increased to 14 percent after 95,47 days.
Source: China International Radio